(Q41387009)

30 September 2017

1 reference

title

Bisphosphonates: preclinical aspects and use in osteoporosis (English)

1 reference

30 September 2017

Fleisch HA

1

1 reference

PubMed ID

9073324

30 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

30 September 2017

1 reference

30 September 2017

29

1 reference

30 September 2017

55-62

1 reference

30 September 2017

1

1 reference

Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

30 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Bisphosphonates: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Etidronate disodium in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Prevention of postmenopausal bone loss by tiludronate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07853899708998743

10.3109/07853899708998743

21 January 2018

Identifiers

DOI

1 reference

30 September 2017

1 reference

PubMed ID

9073324